From a therapeutic perspective, tumor cell aerobic glycolysis associates with a reduced expression of major histocompatibility complex (MHC) proteins [114,115], which are known to confer differential sensitivity to CTLA-4 and PD-1 blockade [116]. The gene discussed is PDCD1; the disease is neoplasm.